MX2014001190A - Solucion inyectable de al menos insulina basal. - Google Patents

Solucion inyectable de al menos insulina basal.

Info

Publication number
MX2014001190A
MX2014001190A MX2014001190A MX2014001190A MX2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A
Authority
MX
Mexico
Prior art keywords
type
basal insulin
radicals
injectable solution
cooh
Prior art date
Application number
MX2014001190A
Other languages
English (en)
Spanish (es)
Inventor
Olivier Soula
GéRARD SOULA
Jeff Tonnar
Alexandre Geissler
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1157291A external-priority patent/FR2978918B1/fr
Priority claimed from FR1162445A external-priority patent/FR2984749A1/fr
Application filed by Adocia filed Critical Adocia
Publication of MX2014001190A publication Critical patent/MX2014001190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2014001190A 2011-08-10 2012-08-09 Solucion inyectable de al menos insulina basal. MX2014001190A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161522031P 2011-08-10 2011-08-10
FR1157291A FR2978918B1 (fr) 2011-08-10 2011-08-10 Solution injectable a ph7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5
US201161579966P 2011-12-23 2011-12-23
FR1162445A FR2984749A1 (fr) 2011-12-23 2011-12-23 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
PCT/FR2012/051880 WO2013021143A1 (fr) 2011-08-10 2012-08-09 Solution injectable d'au moins une insuline basale

Publications (1)

Publication Number Publication Date
MX2014001190A true MX2014001190A (es) 2014-05-12

Family

ID=47667929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001190A MX2014001190A (es) 2011-08-10 2012-08-09 Solucion inyectable de al menos insulina basal.

Country Status (14)

Country Link
US (3) US9089476B2 (enExample)
EP (2) EP3053590A1 (enExample)
JP (1) JP5950477B2 (enExample)
KR (1) KR101810055B1 (enExample)
CN (1) CN103889442B (enExample)
AU (1) AU2012293463B2 (enExample)
BR (1) BR112014002986A2 (enExample)
CA (1) CA2843586A1 (enExample)
DK (1) DK2741765T3 (enExample)
IL (1) IL230611A (enExample)
MX (1) MX2014001190A (enExample)
RU (1) RU2578460C2 (enExample)
WO (1) WO2013021143A1 (enExample)
ZA (1) ZA201400773B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013021143A1 (fr) 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
BR112014016889A8 (pt) 2012-01-09 2017-07-04 Adocia composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
FR3001895B1 (fr) * 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
ES2670969T3 (es) 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
AU2014326181A1 (en) 2013-09-30 2016-03-17 Wockhardt Limited Pharmaceutical composition
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
FR3020952B1 (fr) * 2014-05-14 2017-09-08 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
US9795678B2 (en) * 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CA2995392C (en) * 2015-09-04 2023-08-15 Hailiang Chen Stabilized glucagon solutions
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
EP3377038A1 (fr) * 2015-11-16 2018-09-26 Adocia Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
US20210187078A1 (en) * 2016-02-25 2021-06-24 Wockhardt Limited Pharmaceutical composition of insulin glargine and amino acids
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
FR3052072A1 (fr) 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
EP3518893A1 (en) 2016-09-29 2019-08-07 Arecor Limited Novel formulations
EP3562500B1 (fr) * 2016-12-27 2023-07-19 Adocia Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3070264A1 (fr) 2017-08-24 2019-03-01 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
EP3720472A1 (fr) 2017-12-06 2020-10-14 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) 2018-06-29 2020-10-02 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
JP7637965B2 (ja) 2017-12-07 2025-03-03 アドシア ５．８～８．５のｐＩを有する少なくとも１つの基礎インスリンならびにカルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むｐＨ７の注射溶液
MX2020005914A (es) 2017-12-07 2020-10-19 Adocia Solución inyectable con un ph 7 de 7 que incluye al menos una insulina basal con un pi de entre 5.8 y 8.5 y un copoliaminoácido con cargas de carboxilato y radicales hidrofóbicos.
IL275192B2 (en) 2017-12-07 2025-06-01 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
CA3094237A1 (en) * 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
WO2019193351A1 (en) * 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
IL277731B2 (en) * 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
JP2021528474A (ja) * 2018-06-29 2021-10-21 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ エステルアミン塩
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2387201A (en) 1942-01-12 1945-10-16 Bonneville Ltd Mono-acyl ethylene diamines
EP0160103B1 (en) 1983-10-26 1990-06-20 Kanebo, Ltd. Proteinous emulsifier, process for its preparation, and emulsified cosmetic preparation containing same
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US6599498B1 (en) 1999-04-09 2003-07-29 Advanced Magnetics, Inc. Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
IL140844A0 (en) 2001-01-10 2002-02-10 Polygene Ltd Cationic polysaccharide compositions
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
JP4970731B2 (ja) 2002-12-04 2012-07-11 フラメル・テクノロジー 少なくとも１つの（オリゴ）アミノ酸基によって官能性をもたせたポリアミノ酸およびこれらの適用、特に医療適用
US20060217290A1 (en) 2003-04-29 2006-09-28 Kohn Wayne D Insulin analogs having protracted time action
PT1687019T (pt) * 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
FR2862536B1 (fr) 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2873040B1 (fr) 2004-07-19 2007-11-30 Flamel Technologies Sa Formulation colloidale d'insuline longue action et sa preparation
JP5248113B2 (ja) 2004-11-12 2013-07-31 ノヴォ ノルディスク アー／エス ペプチドの安定な処方
US20060188555A1 (en) 2005-01-21 2006-08-24 Micheal Cormier Therapeutic peptide formulations with improved stability
WO2007116143A1 (fr) * 2006-04-07 2007-10-18 Adocia Polysaccharides bifonctionnalises
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
FR2902007B1 (fr) 2006-06-09 2012-01-13 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
CN101528749B (zh) 2006-09-07 2013-07-31 工业研究有限公司 核苷磷酸化酶和水解酶的无环胺抑制剂
FR2915683B1 (fr) 2007-05-03 2009-08-07 Flamel Technologies Sa Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
FR2919188B1 (fr) 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
CN101778862B (zh) 2007-08-13 2014-12-17 诺沃-诺迪斯克有限公司 快速作用的胰岛素类似物
WO2009063072A2 (en) 2007-11-16 2009-05-22 Novo Nordisk A/S Pharmaceutical compositions containing insulin and an insulinotropic peptide
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US20100069292A1 (en) * 2008-09-02 2010-03-18 Biodel, Inc. Insulin with a basal release profile
US20100167984A1 (en) 2008-09-26 2010-07-01 Adocia Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation
FR2940802A1 (fr) * 2008-10-10 2010-07-09 Adocia Complexe entre l'insuline humaine et un polymere amphiphile et utilisation de ce complexe pour la preparation d'une formulation d'insuline humaine rapide.
US8426382B2 (en) * 2008-10-06 2013-04-23 Adocia Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative
FR2936800B1 (fr) * 2008-10-06 2010-12-31 Adocia Polysaccharide comportant des groupes fonctionnels carboxyles substitues par un derive d'alcool hydrophobe
EP2360188B1 (en) 2008-11-05 2014-09-17 National University Corporation Tokyo Medical and Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
EP2350296A4 (en) 2008-11-17 2013-04-03 Enzon Pharmaceuticals Inc BRANCHED CATIONIC LIPIDS FOR THE SYSTEM FOR INTRODUCING NUCLEIC ACIDS
FR2948573B1 (fr) * 2009-07-31 2011-11-18 Adocia Nouvelle forme d'administration de complexes de proteines osteogeniques
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
EP2376523A4 (en) * 2009-01-13 2012-11-28 Ge Healthcare Bio Sciences Ab PRECIPITATION OF BIOMOLECULES USING NEGATIVELY LOADED POLYMERS
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2956116A1 (fr) * 2010-02-09 2011-08-12 Adocia Complexes polysaccharide/bmp-7 solubles a ph physiologique
FR2958646B1 (fr) * 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
WO2011098962A2 (fr) * 2010-02-09 2011-08-18 Adocia Polysaccharides anioniques fonctionnalisés par au moins deux groupements hydrophobes portés par un spacer au moins trivalent
FR2958647B1 (fr) 2010-04-08 2013-08-23 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent.
EP2388723A1 (en) 2010-05-18 2011-11-23 University College Cork-National University of Ireland, Cork Method of assessing allergic status in a subject
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
WO2012153070A1 (fr) 2011-05-10 2012-11-15 Adocia Oligosaccharides fonctionnalisés
US20120295833A1 (en) 2011-05-10 2012-11-22 Adocia Polysaccharides having an adjustable degree of functionalization
WO2013021143A1 (fr) 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
BR112014016889A8 (pt) 2012-01-09 2017-07-04 Adocia composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
FR2985428B1 (fr) 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
FR2985429B1 (fr) 2012-01-09 2016-07-29 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
CA2902256A1 (en) 2012-02-17 2013-08-22 Massachusetts Institute Of Technology Self-regulated peptide hydrogel for insulin delivery
CN111494638A (zh) 2012-11-13 2020-08-07 阿道恰公司 由离散数个糖单元组成的骨架组成的经取代阴离子化合物
ES2670969T3 (es) 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido

Also Published As

Publication number Publication date
AU2012293463B2 (en) 2016-08-04
KR20140051384A (ko) 2014-04-30
WO2013021143A1 (fr) 2013-02-14
EP2741765B9 (fr) 2016-09-28
EP3053590A1 (fr) 2016-08-10
IL230611A0 (en) 2014-03-31
IL230611A (en) 2016-10-31
DK2741765T3 (en) 2016-06-13
JP2014521716A (ja) 2014-08-28
BR112014002986A2 (pt) 2017-06-13
EP2741765A1 (fr) 2014-06-18
US9089476B2 (en) 2015-07-28
RU2014108829A (ru) 2015-09-20
EP2741765B1 (fr) 2016-03-30
ZA201400773B (en) 2016-11-30
JP5950477B2 (ja) 2016-07-13
US20150250858A1 (en) 2015-09-10
AU2012293463A1 (en) 2014-03-06
CA2843586A1 (fr) 2013-02-14
KR101810055B1 (ko) 2017-12-18
US20170182131A9 (en) 2017-06-29
US20130065826A1 (en) 2013-03-14
US20180311316A1 (en) 2018-11-01
CN103889442A (zh) 2014-06-25
CN103889442B (zh) 2016-12-28
RU2578460C2 (ru) 2016-03-27

Similar Documents

Publication Publication Date Title
SA518400588B1 (ar) محلول قابل للحقن عند الرقم الهيدروجيني 7يشتمل على أنسولين قاعدي واحد على (pi)الأقل تتراوح نقطة التعادل الكهربائي الخاصة به من5.8إلى8.5وحمض بولي أميني مشترك يحمل شحنات كربوكسيلات وجذور كارهة للماء
CA2877732C (en) Soft tip cannula with interlocking tongues and grooves
MX2025009746A (es) Solucion inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoacido con cargas de carboxilato y radicales hidrofobicos
MY192981A (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
EA202090053A3 (ru) Способы и композиции для лечения неэффективного эритропоэза
MX350075B (es) Hidroxido de carbonato de lantano, oxicarbonato de lantano y metodos para su fabricacion y uso.
NZ598520A (en) Probiotic stabilization
AU2012282543A8 (en) Hydrophobised calcium carbonate particles
MX364175B (es) Edulcorante de estevia altamente soluble.
MX348831B (es) Administración parenteral de tapentadol.
BR112012018674A2 (pt) usos de pelo menos uma polietilenimina, e de uma suspensão, e, método para aumentar o ph de uma suspensão aquosa
BR112013005398A2 (pt) "método para aumentar a estabilidade de um licor do processo bayer"
PH12015501479A1 (en) Diclofenac composition
TN2012000516A1 (en) Stable ready to use injectable paracetamol formulation
BR112013030068A2 (pt) grânulos de controle biológico estabilizados dispersíveis em água
BR112014012688A2 (pt) elemento e método de compensação de flutuação
PH12015500863A1 (en) Handleable calco-magnesian suspension
BR112014010053A2 (pt) variantes de isopreno sintase com solubilidade aprimorada para produção de isopreno
UA103290C2 (ru) Фармацевтическая композиция ибупрофена для инъекции
BR112012002453A2 (pt) uso de 2-amino-2-metil-1-propanol(amp),e, método para aumentar o ph de uma suspensão aquosa.
BR112014014623A2 (pt) corpo moldado em resina para revestimento eletrostático
EA201400606A1 (ru) Полиолефиновое волокно
PE20121481A1 (es) Formulacion de liberacion sostenida
EA200900836A1 (ru) Способ получения высокочистой внутренней соли 3-карбокси-n,n,n-триметил-1-пропанаминий гидроксида
BR112012018427A2 (pt) uso de composto, e, método para aumentar o ph de uma suspensão aquosa

Legal Events

Date Code Title Description
FG Grant or registration